Psychosocial health and levels of employment in 851 hypopituitary Swedish patients on long-term GH therapy
2013 (English)In: Psychoneuroendocrinology, ISSN 0306-4530, E-ISSN 1873-3360, Vol. 38, no 6, 842-852 p.Article in journal (Refereed) Published
Context: The psychosocial health and working capacity in hypopituitary patients receiving long-term growth hormone (GH) therapy are unknown. less thanbrgreater than less thanbrgreater thanObjective: Psychosocial health and levels of employment were compared between GH deficient (GHD) patients on long-term replacement and the general population. less thanbrgreater than less thanbrgreater thanDesign and participants: In a Swedish nationwide study, 851 GHD patients [101 childhood onset (CO) and 750 adult onset (AO)] and 2622 population controls answered a questionnaire regarding current living, employment and educational level, alcohol consumption and smoking habits. The median time on GH therapy for both men and women with CO GHD was 9 years and for AO GHD 6 years, respectively. less thanbrgreater than less thanbrgreater thanResults: As compared to the controls, the GHD patients were less often working full time, more often on sick leave/disability pension, and to a larger extent alcohol abstainers and never smokers (all; P andlt; 0.05). Predominantly CO GHD women and men, but to some extent also AO GHD women and men, lived less frequently with a partner and more often with their parents. Particularly AO GHD craniopharyngioma women used more antidepressants, while AO GHD men with a craniopharyngioma used more analgesics. less thanbrgreater than less thanbrgreater thanConclusions: A working capacity to the level of the general population was not achieved among hypopituitary patients, although receiving long-term GH therapy. Patients were less likely to use alcohol and tobacco. The CO GHD population lived a less independent life.
Place, publisher, year, edition, pages
Elsevier , 2013. Vol. 38, no 6, 842-852 p.
Psychosocial health employment, Hypopituitarism, Long-term hormone replacement, GH deficiency, GH therapy
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-95504DOI: 10.1016/j.psyneuen.2012.09.008ISI: 000319540000011OAI: oai:DiVA.org:liu-95504DiVA: diva2:635750
Funding Agencies|Swedish Research Council||Swedish Childhood Cancer Society||2013-07-052013-07-052014-02-17